{"filing":{"accession_number":"0001213900-26-069044","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-06-16","report_date":null,"primary_document":"ea0294921-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026069044/ea0294921-6k_clearmind.htm"},"events":[{"id":12335,"run_id":10903,"accession_number":"0001213900-26-069044","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces the successful completion of dosing for Part A of Clearmind's Phase I/II clinical trial for CMND-100 in treating Alcohol Use Disorder. The disclosure reports a material clinical development milestone—completion of dosing for all 24 participants across four cohorts with positive interim safety results—that would affect a reasonable investor's assessment of the company's drug development progress. While not fitting a discrete event category like earnings or M\u0026A, this represents a significant operational/clinical advancement for a clinical-stage biotech company under FDA oversight.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-06-16","form":"6-K","submitted_at":null,"items":[{"id":9158,"accession_number":"0001213900-26-069044","item_number":"EX-99.1","item_title":"ea029492102ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the successful completion of dosing for Part A of Clearmind's Phase I/II clinical trial for CMND-100 in treating Alcohol Use Disorder. The disclosure reports a material clinical development milestone—completion of dosing for all 24 participants across four cohorts with positive interim safety results—that would affect a reasonable investor's assessment of the company's drug development progress. While not fitting a discrete event category like earnings or M\u0026A, this represents a significant operational/clinical advancement for a clinical-stage biotech company under FDA oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:38:34.913544+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9158,"accession_number":"0001213900-26-069044","item_number":"EX-99.1","item_title":"ea029492102ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the successful completion of dosing for Part A of Clearmind's Phase I/II clinical trial for CMND-100 in treating Alcohol Use Disorder. The disclosure reports a material clinical development milestone—completion of dosing for all 24 participants across four cohorts with positive interim safety results—that would affect a reasonable investor's assessment of the company's drug development progress. While not fitting a discrete event category like earnings or M\u0026A, this represents a significant operational/clinical advancement for a clinical-stage biotech company under FDA oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:38:34.913544+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-06-16"}]}